<DOC>
	<DOCNO>NCT02832778</DOCNO>
	<brief_summary>The purpose study measure drug level blood HIV-infected individual take anti- HIV medication efavirenz 400 mg daily presence anti-TB medication rifampicin isoniazid . The study run two-stages - London ( Stage 1 ) Kampala ( Stage 2 ) . In London ( Stage 1 ) : HIV-1 infected patient ( without tuberculosis infection ) establish treatment combination base 600 mg efavirenz dose recruit . In Kampala ( Stage 2 ) : Patients HIV-1 tuberculosis infection treat 600 mg efavirenz combination HIV AND undergo TB treatment dual therapy regimen contaning rifampicin isoniazid recruit . Efavirenz-containing regimen recommend first-line therapy HIV-TB co-infected patient . It show lack significant difference efavirenz 400 mg efavirenz 600 mg , indicate 400 mg efavirenz non-inferior standard dose . The advantage antiretroviral dose reduction may translate great benefit individual infect HIV globally , since may allow access program reach high number infect patient compensate finite global manufacturing capacity increase demand . For efavirenz , significant price reduction achieve elimination trade , logistics manufacture capacity barrier , price reduction could achieve significant reduction cost pharmaceutical ingredient . However , data PK effectiveness efavirenz 400 mg daily TB treatment produce . Given many patient Efavirenz- base ART need treat TB lifetime rifampicin one commonly use treatment tuberculosis , important study reduce dose carefully monitor condition prior roll low dose standard treatment . Therefore , aim investigate PK efavirenz 400 mg daily HIV-infected individual presence rifampicin isoniazid London , UK HIV/TB-co-infected individual dual anti-TB treatment Kampala , Uganda</brief_summary>
	<brief_title>Pharmacokinetics Efavirenz Presence Rifampicin Isoniazid</brief_title>
	<detailed_description>Protocol Number : SSAT 062 EudraCT Number : 2014-002608-26 Name Investigational Product : Sustiva/Stocrin/Atripla ; Rifinah local generic 300/150 Name active ingredient : Efavirenz/ rifampicin/ isoniazid Study title : Steady-state pharmacokinetics efavirenz ( Sustiva/Stocrin ) 400 mg daily presence rifampicin isoniazid ( Rifinah local generic ) Name Non Investigational Medicinal Product : 2 nucleoside reverse transcriptase inhibitor ( Tenofovir/ emtricitabine tenofovir/lamivudine zidovudine/lamivudine ) Phase study : Phase I Objectives : The objective study : Primary : 1 . To evaluate steady-state pharmacokinetics efavirenz ( Sustiva/Stocrin ) 400 mg daily co-administration rifampicin isoniazid ( Rifinah local generic ) Secondary : 1 . To assess safety tolerability efavirenz ( Sustiva/Stocrin ) 400 mg daily co-administration rifampicin isoniazid ( Rifinah local generic ) 2 . To investigate association genetic polymorphism drug disposition gene drug exposure 3 . Exploratory : To investigate impact anti-retroviral drug platelet function people live HIV Study design : Two-centre , two-stage , 98/99 day London ( Stage 1 ) 28 day Kampala ( Stage 2 ) ( exclude screen follow ) , open-label , pharmacokinetic study Indication : London : HIV-1 infected patient ( without tuberculosis infection ) establish treatment combination base 600 mg efavirenz dose Kampala : Patient HIV-1 tuberculosis infection treat 600 mg efavirenz combination HIV AND undergo TB treatment dual therapy regimen contaning rifampicin isoniazid Methodology : Measurements efavirenz concentration efavirenz pharmacokinetic profile absence ( Stage 1 ) presence rifampicin isoniazid two population HIV-infected individual : 1. without TB ( Stage 1 , London ) 2. TB ( Stage 2 , Kampala ) Planned sample size : Stage 1 , London : For sequential design , sample size 25 patient would provide least 80 % power detect decrease efavirenz Cmin 20 % combine rifampicin/isoniazid-efavirenz phase , compare efavirenz alone phase . Up 40 subject may screen enrol 25 HIV-infected patient complete study . Stage 2 , Kampala : A pilot study 10 patient Uganda HIV TB co-infection anti-HIV treatment anti-TB treatment also perform validate finding London PK study TB-infected population . Up 25 subject may screen enrol 10 HIV/TB-co-infected patient complete pilot sub-study Summary eligibility criterion : Stage 1 , London : HIV-1 infected male female least 18 year , treat stable efavirenz base combination regimen ( tenofovir/ emtricitabine tenofovir/lamivudine zidovudine/lamivudine ) least precede 12 week undetectable viral load CD4+ T-cell count &gt; 100 cell/mm3 . Stage 2 , Kampala : HIV-1 infected male female least 18 year , treat stable efavirenz base combination regimen ( tenofovir /emtricitabine tenofovir/lamivudine zidovudine/lamivudine ) least precede 12 week , CD4+ T-cell count &gt; 100 cell/mm3 , co-infected TB undergo anti-TB treatment rifampicin isoniazid-containing regimen . Duration treatment : London : 98 / 99 ( +/- 1 ) day ( exclude screen follow visit ) Kampala : 28 day ( +/- 7 ) day ( exclude screen follow visit ) Dose route administration : All study drug administer orally subject follow schedule : Stage 1 , London : - Phase 1 ( 2 week ) : tenofovir/emtricitabine tenofovir/lamivudine zidovudine/lamivudine plus efavirenz ( Sustiva/Stocrin ) 400 mg daily - Phase 2 ( 12 week ) : tenofovir/emtricitabine tenofovir /lamivudine zidovudine/lamivudine ) plus efavirenz ( Sustiva/Stocrin ) 400 mg daily plus Rifinah local generic daily ( rifampicin 600 mg isoniazid 300 mg ≥50kg rifampicin 450 mg isoniazid 300 mg &lt; 50kg . ) Stage 2 , Kampala : Tenofovir/emtricitabine lamivudine zidovudine/lamivudine plus efavirenz ( Sustiva/Stocrin ) 400 mg daily plus Rifinah local generic daily ( rifampicin 600 mg isoniazid 300 mg ≥ 50 kg rifampicin 450 mg isoniazid 300 mg &lt; 50kg ) . Criteria evaluation : Stage 1 , London : Pharmacokinetic ( PK ) parameter efavirenz evaluate blood drawn day : - 14/15 ( 2 week reduce efavirenz dose 600 mg 400 mg ) - 42/43 ( 4 week Rifinah local generic initiation start phase 2 ) - 98/99 ( 12 week Rifinah local generic initiation ) - PK profile 0 ( pre-dose ) , 2 , 4 , 8 , 12 24 hour post administer dose . Stage 2 , Kampala : Pharmacokinetic parameter efavirenz evaluate blood drawn : - day 28 +/- 7 day ( anti-TB medication ) - PK profile 0 ( pre-dose ) , 2 , 4 , 8 , 12 24 hour post last dose . Safety tolerability medication also assess question collect adverse event symptom , physical examination laboratory parameter , perform regular interval study , include efavirenz therapeutic drug monitoring ( TDM ) once/twice week . Endpoints : Primary endpoint : 1 . Steady state plasma concentration efavirenz administer 400 mg daily presence rifampicin isoniazid Secondary endpoint : 1 . Safety tolerability efavirenz administer 400 mg daily presence rifampicin isoniazid . 2 . Relationship genetic polymorphism exposure efavirenz . 3 . Exploratory : impact anti-retroviral drug platelet function people live HIV .</detailed_description>
	<mesh_term>Rifampin</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<mesh_term>Efavirenz</mesh_term>
	<mesh_term>Emtricitabine</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<mesh_term>Lamivudine , zidovudine drug combination</mesh_term>
	<mesh_term>Isoniazid</mesh_term>
	<criteria>Inclusion Criteria LONDON 1 . Evidence personally sign date informed consent document indicate subject inform pertinent aspect study . 2 . Male nonpregnant , nonlactating female . 3 . HIV1infected antiretroviral regimen contain tenofovir , emtricitabine , lamivudine zidovudine/lamivudine efavirenz 600 mg daily least 12 week . 4 . With undetectable viral load least 12 week ( retesting allow ) . 5 . CD4 count &gt; 100 cells/mm3 . 6 . Between 18 60 year , inclusive . 7 . Body Mass Index ( BMI ) 18 35 kg/m2 , inclusive . 8 . Women childbearing potential ( WOCBP ) must use adequate effective double barrier method contraception ( appendix 4 ) willing continue practise birth control method trial avoid pregnancy period least 12 week last dose study medication . Note : Nonchildbearing potential define either postmenopausal ( 12 month spontaneous amenorrhoea ≥45 year ) physically incapable become pregnant document tubal ligation , hysterectomy bilateral oophorectomy . Adequate contraception method : Condom spermicides Condom Intrauterine device ( IUD/IUS ) 9 . Heterosexually active male , must use effective birth control method willing continue practise birth control method trial followup visit 10 . TB negative accord result ELISPOT test . Inclusion Criteria KAMPALA 1 . Evidence personally sign date informed consent document indicate subject inform pertinent aspect study . 2 . Male nonpregnant , nonlactating female . 3 . HIV1infected antiretroviral regimen contain 2 NRTIs plus efavirenz 600 mg daily least 3 week . 4 . With TB diagnosis currently undergo antiTB treatment rifampicin isoniazidcontaining regimen . 5 . CD4 count &gt; 100 cells/mm3 . 6 . Between 18 60 year , inclusive . 7 . Body Mass Index ( BMI ) 18 35 kg/m2 , inclusive . 8 . Women childbearing potential ( WOCBP ) must use adequate double method contraception avoid pregnancy throughout study period least 12 week last dose study medication Adequate contraception method : Condom spermicides Condom Intrauterine device ( IUD/IUS ) 9 . Heterosexually active male , must use effective birth control method willing continue practise birth control method trial followup visit Exclusion criterion LONDON 1 . Any significant acute chronic medical illness opinion investigator may influence study result patient safety . 2 . Evidence organ dysfunction clinically significant deviation normal physical examination , vital sign , ECG clinical laboratory determination opinion investigator may compromise participation study 3 . Hepatic transaminase ( AST ALT ) &gt; Grade 1 [ 1.252.5 x upper limit normal ( ULN ) ] . 4 . Positive blood screen hepatitis B surface antigen and/or positive hepatitis C Ab and/or PCR . 5 . Clinically relevant alcohol drug use ( positive urine drug screen cannabis allow ) history alcohol drug use consider Investigator sufficient hinder compliance treatment , followup procedure evaluation adverse event . 6 . Exposure investigational drug placebo within one month first dose study drug 7 . Use drug ( unless approve Investigator see section 5.2 ) , include overthecounter medication herbal preparation , within two week prior first dose study drug , unless approved/prescribed Investigator know interact study drug . 8 . Females childbearing potential without use effective nonhormonal birth control method , willing continue practise birth control method least 12 week end treatment period ( See inclusion criterion number 8 ) . 9 . Heterosexual male without use effective nonhormonal birth control method , willing continue practise birth control method least 12 week end treatment period . ( See inclusion criterion number 9 ) . Exclusion criterion KAMPALA 1 . Any significant acute chronic medical illness ( exception TB ) opinion Investigator may affect study result patient safety ( include AIDS event ) 2 . Evidence severe organ dysfunction clinically significant deviation normal physical examination , vital sign , ECG clinical laboratory determination opinion investigator may compromise participation study . 3 . Positive blood screen hepatitis B surface antigen hepatitis C antibody . 4 . History alcohol drug use consider Investigator sufficient hinder compliance treatment , followup procedure evaluation adverse event . 5 . Exposure investigational drug placebo within one month first dose study drug . 6 . Use drug ( unless approve Investigator see section 5.2 ) , include overthecounter medication herbal preparation , within two week prior first dose study drug , unless approved/prescribed Principal Investigator know interact study drug . 7 . Females childbearing potential without use effective nonhormonal birth control method , willing continue practise birth control method least 12 week end treatment period ( see inclusion criterion number 8 ) . 8 . Heterosexual male without use effective nonhormonal birth control method , willing continue practise birth control method least 12 week end treatment period ( See inclusion criterion number 9 appendix 4 ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>